As of 2025, Hikma Pharmaceuticals has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 absolute reduction target, signaling the company's commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Hikma Pharmaceuticals's climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | -25%a | 2030 |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
As of 2025, Hikma Pharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.a
As of 2025, Hikma Pharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.a
Hikma Pharmaceuticals's most ambitious operational target is to reduce these emissions by 25% by 2030, compared to a baseline of 155,142 Metric Tonnes of CO2 equivalent (mtCO2e) in 2020.a
As of 2025, Hikma Pharmaceuticals is ahead of schedule on its operational emissions reduction target, having achieved 70.04% of the planned reduction.a